Literature DB >> 22187433

A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator.

Paul Y Kim1, Long D Tieu, Alan R Stafford, James C Fredenburgh, Jeffrey I Weitz.   

Abstract

Fibrin (Fn) enhances plasminogen (Pg) activation by tissue-type plasminogen activator (tPA) by serving as a template onto which Pg and tPA assemble. To explore the contribution of the Pg/Fn interaction to Fn cofactor activity, Pg variants were generated and their affinities for Fn were determined using surface plasmon resonance (SPR). Glu-Pg, Lys-Pg (des(1-77)), and Mini-Pg (lacking kringles 1-4) bound Fn with K(d) values of 3.1, 0.21, and 24.5 μm, respectively, whereas Micro-Pg (lacking all kringles) did not bind. The kinetics of activation of the Pg variants by tPA were then examined in the absence or presence of Fn. Whereas Fn had no effect on Micro-Pg activation, the catalytic efficiencies of Glu-Pg, Lys-Pg, and Mini-Pg activation in the presence of Fn were 300- to 600-fold higher than in its absence. The retention of Fn cofactor activity with Mini-Pg, which has low affinity for Fn, suggests that Mini-Pg binds the tPA-Fn complex more tightly than tPA alone. To explore this possibility, SPR was used to examine the interaction of Mini-Pg with Fn in the absence or presence of tPA. There was 50% more Mini-Pg binding to Fn in the presence of tPA than in its absence, suggesting that formation of the tPA-Fn complex exposes a cryptic site that binds Mini-Pg. Thus, our data (a) indicate that high affinity binding of Pg to Fn is not essential for Fn cofactor activity, and (b) suggest that kringle 5 localizes and stabilizes Pg within the tPA-Fn complex and contributes to its efficient activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187433      PMCID: PMC3281636          DOI: 10.1074/jbc.M111.317719

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.

Authors:  Mark Schneider; Michael Nesheim
Journal:  J Biol Chem       Date:  2004-01-08       Impact factor: 5.157

2.  Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site.

Authors:  A Motta; R A Laursen; M Llinás; A Tulinsky; C H Park
Journal:  Biochemistry       Date:  1987-06-30       Impact factor: 3.162

3.  Ligand interactions with the kringle 5 domain of plasminogen. A study by 1H NMR spectroscopy.

Authors:  T Thewes; K Constantine; I J Byeon; M Llinás
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

4.  A simple method for preparing fibrinogen.

Authors:  W Straughn; R H Wagner
Journal:  Thromb Diath Haemorrh       Date:  1966-07-31

5.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

Review 6.  Human plasminogen.

Authors:  F J Castellino; J R Powell
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  The binding of human plasminogen to fibrin and fibrinogen.

Authors:  M A Lucas; L J Fretto; P A McKee
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

8.  1H NMR studies of aliphatic ligand binding to human plasminogen kringle 4.

Authors:  A M Petros; V Ramesh; M Llinás
Journal:  Biochemistry       Date:  1989-02-07       Impact factor: 3.162

9.  Isolation and characterization of microplasminogen. A low molecular weight form of plasminogen.

Authors:  G Y Shi; H L Wu
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

10.  The course and prerequisites of Lys-plasminogen formation during fibrinolysis.

Authors:  E Suenson; S Thorsen
Journal:  Biochemistry       Date:  1988-04-05       Impact factor: 3.162

View more
  13 in total

1.  Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.

Authors:  Paul Y Kim; Trang T Vu; Beverly A Leslie; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

2.  Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.

Authors:  Leifeng Cheng; Daniel Pettersen; Bengt Ohlsson; Peter Schell; Michael Karle; Emma Evertsson; Sara Pahlén; Maria Jonforsen; Alleyn T Plowright; Jonas Boström; Tomas Fex; Anders Thelin; Constanze Hilgendorf; Yafeng Xue; Göran Wahlund; Walter Lindberg; Lars-Olof Larsson; David Gustafsson
Journal:  ACS Med Chem Lett       Date:  2014-02-18       Impact factor: 4.345

3.  Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.

Authors:  Dante Disharoon; Brian G Trewyn; Paco S Herson; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2021-12-19       Impact factor: 5.824

4.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

5.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.

Authors:  Ran Ni; Miguel A D Neves; Chengliang Wu; Samantha E Cerroni; Matthew J Flick; Heyu Ni; Jeffrey I Weitz; Peter L Gross; Paul Y Kim
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 5.824

6.  Ultrasound-targeted transfection of tissue-type plasminogen activator gene carried by albumin nanoparticles to dog myocardium to prevent thrombosis after heart mechanical valve replacement.

Authors:  Jun Ji; Shang-Yi Ji; Jian-An Yang; Xia He; Xiao-Han Yang; Wen-Ping Ling; Xiao-Ling Chen
Journal:  Int J Nanomedicine       Date:  2012-06-19

7.  Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

Authors:  Calvin H Yeh; Alan R Stafford; Beverly A Leslie; James C Fredenburgh; Jeffrey I Weitz
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

Review 8.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

Review 9.  Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface.

Authors:  Sophia Bardehle; Victoria A Rafalski; Katerina Akassoglou
Journal:  Front Cell Neurosci       Date:  2015-09-16       Impact factor: 5.505

10.  A novel serine protease secreted by medicinal maggots enhances plasminogen activator-induced fibrinolysis.

Authors:  Mariena J A van der Plas; Anders S Andersen; Sheresma Nazir; Nico H van Tilburg; Peter R Oestergaard; Karen A Krogfelt; Jaap T van Dissel; Paul J Hensbergen; Rogier M Bertina; Peter H Nibbering
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.